Mosapride citrate tablet as well as preparation method and application thereof
Mosapride citrate with hydrophilic polymer excipients and polyvinyl alcohol, and using megamine and triethanolamine as solubilizing aids, a rapid and stable mass of mosapride citrate was prepared by co-granulating mosapride citrate with hydrophilic polymer excipients and polyvinyl alcohol, and using megamine and triethanolamine as solubilization aids. Priligy tablets solve the problem of low dissolution of insoluble drugs and are suitable for industrial production.
Patent Information
- Application Number
- CN202411182630.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-27
- Publication Date
- 2024-11-29
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Mosapride citrate is a difficult-to-soluble drug, which leads to low dissolution of its oral solid preparations and is difficult to meet production requirements.
Mosapriligy citrate in a specific proportion of mosapriligy citrate tablets were prepared by co-granulating with hydrophilic polymer excipients and polyvinyl alcohol, and using megamine and triethanolamine as solubilization aids. , including mosapride citrate co-grinder, filler, disintegrant, lubricant and solubilizer, tableting preparation is carried out.
The mosapriligy citrate tablets have been quickly dissolution and stable in quality. They can basically dissolve them within 45 minutes. The preparation process is simple and suitable for large-scale industrial production.
Smart Images

Figure SMS_3 
Figure SMS_4
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and specifically relates to a mosapride citrate tablet and a preparation method and application thereof. Background Art
[0002] Mosapride is a drug that is a selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that can promote the release of acetylcholine, stimulate the gastrointestinal tract and exert a prokinetic effect, thereby improving The patient's gastrointestinal symptoms, but does not affect the secretion of gastric acid.
[0003] Mosapride has no affinity for dopamine D2 receptors, adrenaline α1 receptors, 5-HT1 and 5-HT2 receptors on the synaptic membranes of brain nerve cells, so it will not cause extrapyramidal syndrome and cardiovascular disease. .
[0004] However, mosapride citrate is a poorly soluble drug that is almost insoluble in water. In the actual production of mosapride citrate oral solid preparations, problems such as low solubility or even substandard preparations are often encountered. Summary of the invention
[0005] In view of this, the object of the present invention is to provide a mosapride citrate tablet and a preparation method and application thereof. The mosapride citrate tablet provided by the present invention has rapid dissolution and stable quality.
[0006] To achieve this object, the present invention adopts the following technical solutions:
[0007] The present invention provides a mosapride citrate tablet, comprising, by weight:
[0008] 10~20 parts of mosapride citrate co-grinding
[0009] Filler 50~150 parts
[0010] Disintegrant 5~10 parts
[0011] 2~5 parts of lubricant
[0012] 5-10 parts of solubilizing agent;
[0013] Wherein, the mosapride citrate co-grinding material is obtained by co-grinding mosapride citrate, a hydrophilic polymer auxiliary material and polyvinyl alcohol;
[0014] The solubilizing aids include meglumine and triethanolamine.
[0015] Preferably, the hydrophilic polymer auxiliary material is selected from any one or more of cyclodextrin, starch or gelatin.
[0016] Preferably, the molecular weight of the polyvinyl alcohol is 20,000 to 300,000.
[0017] Preferably, the mass ratio of mosapride citrate, hydrophilic polymer excipient and polyvinyl alcohol is (15-45):(35-55):(10-35).
[0018] Preferably, the mass ratio of meglumine to triethanolamine is (5-10):1.
[0019] Preferably, the mass ratio of mosapride citrate, hydrophilic polymer excipient and polyvinyl alcohol is (18-40):(36-50):(10-30).
[0020] Preferably, the mass ratio of meglumine to triethanolamine is (6-8):1.
[0021] Preferably, the disintegrant is selected from any one or more of dry starch, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, cross-linked polyvinyl pyrrolidone or sodium carboxymethyl cellulose.
[0022] Preferably, the filler is selected from any one or more of microcrystalline cellulose, silicified microcrystalline cellulose, starch, pre-melted starch, lactose, sucrose, mannitol, sorbitol or dextrin.
[0023] Preferably, the lubricant is selected from one or more of magnesium stearate, talc or silicon dioxide.
[0024] Preferably, the filler is selected from microcrystalline cellulose and lactose, and the mass ratio of the microcrystalline cellulose to lactose is 1:(0.8~1.5).
[0025] The lubricant is selected from magnesium stearate and silicon dioxide, and the mass ratio of magnesium stearate to silicon dioxide is 1:(2~4).
[0026] Preferably, the mosapride citrate tablets comprise, by weight:
[0027] 12~18 parts of mosapride citrate co-grinding
[0028] Filler 60~120 parts
[0029] Disintegrant 6~9 parts
[0030] Lubricant 2.5~4.5 parts
[0031] 6~9 parts of solubilizing agent.
[0032] In a second aspect, the present invention provides a method for preparing the above-mentioned mosapride citrate tablets, comprising:
[0033] The mosapride citrate co-grinding material, filler, disintegrant, lubricant and solubilizing agent are mixed in proportion and then tableted to obtain the mosapride citrate tablets.
[0034] In a third aspect, the present invention provides a use of the above-mentioned mosapride citrate tablets in the preparation of a medicament for relieving gastrointestinal discomfort.
[0035] Compared with the prior art, the present invention has the following beneficial effects:
[0036] The present invention provides a mosapride citrate tablet, which comprises a specific ratio of mosapride citrate co-grinding material, a filler, a disintegrant, a lubricant and a solubilizing agent. The present invention uses mosapride citrate, a hydrophilic polymer auxiliary material and polyvinyl alcohol in combination, and adopts meglumine and triethanolamine as solubilizing agents, which is conducive to the rapid dissolution of the mosapride citrate tablet and stable quality. According to the test, the mosapride citrate tablet provided by the present invention can be basically completely dissolved within 45 minutes.
[0037] In addition, the preparation process of the mosapride citrate tablets provided by the present invention is simple, easy to implement, does not require complex equipment, has strong universality, and is suitable for large-scale industrial or industrialized production. DETAILED DESCRIPTION
[0038] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0039] The present invention provides a mosapride citrate tablet, which comprises, by weight:
[0040] 10~20 parts of mosapride citrate co-grinding
[0041] Filler 50~150 parts
[0042] Disintegrant 5~10 parts
[0043] 2~5 parts of lubricant
[0044] 5~10 parts of solubilizing agent.
[0045] In some embodiments of the present invention, the mosapride citrate tablets comprise, by weight:
[0046] 12~18 parts of mosapride citrate co-grinding
[0047] Filler 60~120 parts
[0048] Disintegrant 6~9 parts
[0049] Lubricant 2.5~4.5 parts
[0050] 6~9 parts of solubilizing agent.
[0051] In some preferred embodiments of the present invention, the mosapride citrate tablets comprise, by weight:
[0052] 13~16 parts of mosapride citrate co-grinding
[0053] Filler 70~100 parts
[0054] Disintegrant 6.5~8 parts
[0055] 3~4 parts of lubricant
[0056] 7~8 parts of solubilizing agent.
[0057] In the present invention, the mosapride citrate co-grinding material is obtained by co-grinding mosapride citrate, hydrophilic polymer excipients and polyvinyl alcohol. The mass ratio of mosapride citrate, hydrophilic polymer excipients and polyvinyl alcohol is (15~45): (35~55): (10~35), preferably (18~40): (36~50): (10~30), more preferably (20~38): (38~50): (12~28). Wherein, the hydrophilic polymer excipient is selected from any one or more of cyclodextrin, starch or gelatin, preferably cyclodextrin, and the cyclodextrin can be α-cyclodextrin or β-cyclodextrin, preferably β-cyclodextrin. The molecular weight of the polyvinyl alcohol is 20,000~300,000, preferably 50,000~250,000, more preferably 100,000~200,000. It should be noted that the present invention co-grinds mosapride citrate, a hydrophilic polymer excipient and polyvinyl alcohol to obtain a mosapride citrate co-grind, which can better release mosapride citrate without a burst release phenomenon, and is conducive to better absorption in the stomach and intestines of an individual.
[0058] In the present invention, the filler is selected from any one or more of microcrystalline cellulose, silicified microcrystalline cellulose, starch, pre-coated starch, lactose, sucrose, mannitol, sorbitol or dextrin. In some embodiments of the present invention, the filler is preferably microcrystalline cellulose and lactose, and the mass ratio of microcrystalline cellulose to lactose is 1:(0.8-1.5), preferably 1:(0.9-1.2), and more preferably 1:1.
[0059] In the present invention, the disintegrant is selected from any one or more of dry starch, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, cross-linked polyvinyl pyrrolidone, or sodium carboxymethyl cellulose. In some embodiments of the present invention, the disintegrant is preferably cross-linked polyvinyl pyrrolidone.
[0060] In the present invention, the lubricant is selected from one or more of magnesium stearate, talc or silicon dioxide. In some embodiments of the present invention, the lubricant is selected from magnesium stearate and silicon dioxide, and the mass ratio of magnesium stearate to silicon dioxide is 1: (2-4), preferably 1: (2.5-3.5), and more preferably 1: 3.
[0061] In the present invention, the solubilizing agent comprises meglumine and triethanolamine, and the mass ratio of meglumine to triethanolamine is (5-10):1, preferably (6-9):1, and more preferably (6.5-8.5):1. It should be noted that, after screening, the combination of meglumine and triethanolamine is used as a solubilizing agent, which is conducive to the rapid dissolution of the obtained mosapride citrate tablets and stable quality.
[0062] The present invention also provides a method for preparing the mosapride citrate tablets, which comprises:
[0063] The mosapride citrate co-grinding material, filler, disintegrant, lubricant and solubilizing agent are mixed in proportion and then tableted to obtain the mosapride citrate tablets.
[0064] In the present invention, the specific operations of mixing and tableting can be performed according to conventional technical means well known to those skilled in the art.
[0065] It can be seen that the preparation process of the mosapride citrate tablets provided by the present invention is simple, easy to implement, does not require complex equipment, has strong universality, and is suitable for large-scale industrial or industrial production.
[0066] In some embodiments of the present invention, the present invention determines the dissolution rate of the obtained mosapride citrate tablets in accordance with the "General Rules of Part Four of the Chinese Pharmacopoeia 2020 Edition 0931 Method 2", and the results show that the mosapride citrate tablets can be basically completely dissolved within 45 minutes, which shows that the dissolution rate is fast and the dissolution quality is stable.
[0067] Based on this, the present invention also provides an application of the above-mentioned mosapride citrate tablets in the preparation of a medicine for relieving gastrointestinal discomfort.
[0068] In order to further illustrate the present invention, the following examples are used to describe the present invention in detail. The experimental raw materials used in the following examples of the present invention are all common commercial products. Among them, the molecular weight of the polyvinyl alcohol involved below is 20,000 to 300,000.
[0069] Preparation Example 1
[0070] 7.50 g of mosapride citrate, 17.6 g of β-cyclodextrin and 6.8 g of polyvinyl alcohol were divided into three parts and placed in a ball mill. First, one third of the above mixture was added to the dry mixer and mixed at 15 r / min for 7 min. Then, the second part of the mixture was added to the dry mixer and mixed at 15 r / min for 7 min. Finally, the remaining mixture was added to the dry mixer and dry mixed at 15 r / min for 7 min to obtain the mosapride citrate co-grinding material.
[0071] Preparation Example 2
[0072] 8.60 g of mosapride citrate, 19.3 g of β-cyclodextrin and 7.34 g of polyvinyl alcohol were divided into three parts and placed in a ball mill. First, one third of the above mixture was added to the dry mixer and mixed at 19 r / min for 8 min. Then, the second part of the mixture was added to the dry mixer and mixed at 19 r / min for 8 min. Finally, the remaining mixture was added to the dry mixer and dry mixed at 19 r / min for 8 min to obtain the mosapride citrate co-grinding material.
[0073] Preparation Example 3
[0074] 7.90 g of mosapride citrate, 18.7 g of β-cyclodextrin and 7.23 g of polyvinyl alcohol were divided into three parts and placed in a ball mill. First, one third of the above mixture was added to the dry mixer and mixed at 17 r / min for 10 min. Then, the second part of the mixture was added to the dry mixer and mixed at 17 r / min for 10 min. Finally, the remaining mixture was added to the dry mixer and dry mixed at 17 r / min for 10 min to obtain the mosapride citrate co-grinding material.
[0075] Comparative Preparation Example 1
[0076] Compared with Preparation Example 1, polyvinyl alcohol was not added, and the other parameters and steps were consistent with Preparation Example 1.
[0077] Comparative Preparation Example 2
[0078] Compared with Preparation Example 1, an equal amount of polyvinyl alcohol was replaced by polyethylene glycol, and the other parameters and steps were consistent with Preparation Example 1.
[0079] Verification Example
[0080] According to the "General Rules of Part IV of the 2020 Edition of the Chinese Pharmacopoeia 0931 Method 2", the solubility of the co-grinded mosapride citrate obtained in Preparation Examples 1 to 3 and Comparative Preparation Examples 1 to 3 was determined, and the results are shown in Table 1.
[0081] Table 1
[0082]
[0083] Example 1
[0084] The co-grinded mosapride citrate of Preparation Example 1 of the present invention is mixed with auxiliary materials and then tableted to obtain mosapride citrate tablets.
[0085] The formula of the mosapride citrate tablets is as follows (the solubilizing agent includes 5 parts of meglumine and 1 part of triethanolamine by weight):
[0086] Mosapride citrate co-grinding 15g
[0087] Microcrystalline cellulose 60g
[0088] Lactose 60g
[0089] Cross-linked polyvinylpyrrolidone 5g
[0090] Solubilizing agent 10g
[0091] Magnesium stearate 1g
[0092] Silicon dioxide 3g
[0093] Made into 1000 pieces.
[0094] Example 2
[0095] Compared with Example 1, the difference is that the mosapride citrate co-grinding material is the material obtained in Preparation Example 2, the solubilizing aid includes 8 parts of meglumine and 1 part of triethanolamine by weight, and the other parameters and steps are consistent with Example 1.
[0096] Example 3
[0097] Compared with Example 1, the difference is that the mosapride citrate co-grinding material is the material obtained in Preparation Example 3, the solubilizing aid includes 10 parts of meglumine and 1 part of triethanolamine by weight, and the other parameters and steps are consistent with Example 1.
[0098] Comparative Example 1
[0099] Compared with Example 1, the only difference is that the mosapride citrate co-grinding material is the material obtained in Comparative Preparation Example 1, and the other parameters and steps are consistent with Example 1.
[0100] Comparative Example 2
[0101] Compared with Example 1, the only difference is that the mosapride citrate co-grinding material is the material obtained in Comparative Preparation Example 2, and the other parameters and steps are consistent with Example 1.
[0102] Comparative Example 3
[0103] Compared with Example 1, the only difference is that the solubilizing aid only includes meglumine, and the other parameters and steps are consistent with Example 1.
[0104] Comparative Example 4
[0105] Compared with Example 1, the only difference is that the solubilizing aid only includes triethanolamine, and the other parameters and steps are consistent with Example 1.
[0106] Comparative Example 5
[0107] Compared with Example 1, the only difference is that the triethanolamine in the solubilizing agent is replaced by triethylamine in an equal amount, and the other parameters and steps are consistent with Example 1.
[0108] Verification Example
[0109] Dissolution determination: According to the "Chinese Pharmacopoeia 2020 Edition Four General Rules 0931 Second Method", the mosapride citrate tablets obtained in Examples 1 to 3 and Comparative Examples 1 to 5 were measured, with 900mL of 0.1mol / L hydrochloric acid solution as the dissolution medium, the speed was 75rpm per minute, and the solution was taken 10mL after 5 min, 30 min and 45 min, filtered, and the filtrate was taken as the test solution, and 0.1mol / L hydrochloric acid 10mL was supplemented at the same time; Mosapride citrate reference substance was taken separately, 65mg was accurately weighed, placed in a 100mL volumetric flask, methanol was added to dilute and set the volume, 5mL of solution was accurately pipetted to a 100mL volumetric flask with a pipette, methanol was added to dilute and set the volume, 5mL of solution was accurately pipetted to a volumetric flask with a pipette, methanol was added to dilute and set the volume, and shaken well as a reference solution. Take the above two solutions, detect them by HPLC, and calculate the cumulative release, and the results are shown in Table 2.
[0110] Table 2
[0111]
[0112] The above description of the disclosed embodiments enables those skilled in the art to implement or use the present invention. Various modifications to these embodiments will be apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and novel features disclosed herein.
Claims
1. A mosapride citrate tablet, It is characterized in that In parts by weight: 10~20 parts of mosapride citrate co-grinding Filler 50~150 parts Disintegrant 5~10 parts 2~5 parts of lubricant 5-10 parts of solubilizing agent; Wherein, the mosapride citrate co-grinding material is obtained by co-grinding mosapride citrate, a hydrophilic polymer auxiliary material and polyvinyl alcohol; The solubilizing aids include meglumine and triethanolamine.
2. The mosapride citrate tablets according to claim 1, It is characterized in that The hydrophilic polymer auxiliary material is selected from any one or more of cyclodextrin, starch or gelatin.
3. The mosapride citrate tablets according to claim 1 or 2, It is characterized in that The molecular weight of the polyvinyl alcohol is 20,000 to 300,000.
4. The mosapride citrate tablets according to any one of claims 1 to 3, It is characterized in that The mass ratio of mosapride citrate, hydrophilic polymer auxiliary material and polyvinyl alcohol is (15-45):(35-55):(10-35); The mass ratio of the meglumine to triethanolamine is (5-10):
1.
5. The mosapride citrate tablets according to claim 4, It is characterized in that The mass ratio of mosapride citrate, hydrophilic polymer auxiliary material and polyvinyl alcohol is (18-40):(36-50):(10-30); The mass ratio of meglumine to triethanolamine is (6-8):
1.
6. The mosapride citrate tablets according to any one of claims 1 to 5, It is characterized in that The disintegrant is selected from any one or more of dry starch, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, cross-linked polyvinyl pyrrolidone or sodium carboxymethyl cellulose; The filler is selected from any one or more of microcrystalline cellulose, silicified microcrystalline cellulose, starch, pre-melted starch, lactose, sucrose, mannitol, sorbitol or dextrin; The lubricant is selected from one or more of magnesium stearate, talc or silicon dioxide.
7. The mosapride citrate tablets according to claim 6, It is characterized in that The filler is selected from microcrystalline cellulose and lactose, the mass ratio of microcrystalline cellulose and lactose is 1: (0.8 ~ 1.5); The lubricant is selected from magnesium stearate and silicon dioxide, and the mass ratio of magnesium stearate to silicon dioxide is 1:(2~4).
8. The mosapride citrate tablets according to any one of claims 1 to 7, It is characterized in that The mosapride citrate tablets comprise, by weight: 12~18 parts of mosapride citrate co-grinding Filler 60~120 parts Disintegrant 6~9 parts Lubricant 2.5~4.5 parts 6~9 parts of solubilizing agent.
9. A method for preparing the mosapride citrate tablets according to any one of claims 1 to 8, It is characterized in that include: The mosapride citrate co-grinding material, filler, disintegrant, lubricant and solubilizing agent are mixed in proportion and then tableted to obtain the mosapride citrate tablets.
10. The mosapride citrate tablets according to any one of claims 1 to 8 or Use of the mosapride citrate tablets prepared by the preparation method according to claim 9 in the preparation of a medicament for relieving gastrointestinal discomfort.
Citation Information
Patent Citations
Mosapride citrate co-grinded product, preparation method thereof and medicine composition containing mosapride citrate co-grinded product
CN104546686A
Solid dispersions of compounds using polyvinyl alcohol as carrier polymer
CN107205935A
Solid dispersion comprising an anticancer compound for improved solubility and efficacy
US20210308116A1
Solid dispersion, preparation method therefor, and solid formulation containing same
WO2023078265A1
